vides an objective measure of prognosis for those patients who require a decompressive craniectomy. [15] [16] [17] In terms of developing secondary brain injury, for many years intracranial pressure (ICP) has been used as a means of assessment with little doubt of its prognostic value. 3, 20, 21 However, use of ICP as a measure has some limitations as it becomes increasingly apparent that it is essentially a measure of end organ injury, demonstrated by the failure of many ICP-lowering therapies to improve outcome. 6, 9, 41 Barbiturates and hypothermia certainly have the potential to be neuroprotective because of their effect on some cellular responses to injury; 31, 32 however, the predominant mechanism by which they reduce ICP, along with hyperventilation, is their effect on cerebral vasculature. 9, 30, 33 An additional limitation is the considerable range of ICPs that patients can tolerate. 28, 29 In attempts to address some of these issues and provide additional prognostic information, a number of multimodal monitoring techniques that can obtain continuous data regarding various physiological and biochemical parameters have been developed. These techniques include jugular venous bulb monitoring, 11 brain tissue oxygenation, 23 ,39 microdialysis, 26, 38 and continuous monitoring with electroencephalography. 40 However, aside from the large amount of data that these monitoring techniques provide, none has been found to have significant independent predictive value significance. 4, 20, 38, 42, 43 Our aim with this study was to determine whether disruption of the blood-brain barrier (BBB) could act as a marker of secondary brain injury and therefore provide independent prognostic information.
Methods
After obtaining Royal Perth Hospital Ethics Committee approval, 2 investigators independently retrieved the biochemical data of patients who had undergone decompressive craniectomy during 2004-2012 at 2 neurotrauma centers in Western Australia. They linked the data to the decompressive craniectomy database. The clinical and outcome data were collected prospectively from the decompressive craniectomy database, and the biochemical data were collected retrospectively from the centralized laboratory database. All CSF and plasma samples were obtained on the same day as part of clinical management for patients with an external ventricular drain (EVD). The management strategies and outcomes of patients who had severe TBI requiring decompressive craniectomy before 2011 are described in our previous publications. 15, 16 In this study, we defined BBB disruption as a total CSF protein concentration to total plasma protein concentration ratio greater than 0.007, which correlates well with the traditional biochemical marker of BBB disruption (CSF-plasma albumin quotient [correlation coefficient 0.97]). 34 Because the BBB can be disrupted across a continuum of severity, we also assessed the prognostic significance of BBB disruption by analyzing the ratio of the total CSF protein concentrations to total plasma protein concentrations as a continuous variable. When more than 1 sample of CSF was obtained from the same patient, we analyzed the first sample collected after TBI.
Statistical Analyses
Categorical and continuous variables were analyzed by using the chi-square and Mann-Whitney tests, respectively. Multivariate logistic regression analyses were used to identify factors associated with BBB disruption. Because of the small study sample, a parsimony model was generated to increase the precision of the results by stepwise removal of factors that were associated with a p value greater than 0.25. We used the area under the receiver operating characteristic (ROC) curve to assess the ability of the CSF protein to plasma protein ratio and risks for unfavorable outcome predicted by the Corticosteroid Randomization after Significant Head Injury (CRASH) prognostic model 23 to differentiate between unfavorable and favorable outcomes at 18 months after decompressive craniectomy. We also used the area under the ROC curve to assess whether combining information on BBB disruption with the CRASH model predicted risks for unfavorable outcome would improve the predictive ability of the CRASH model. We used the method recommended by Hanley and McNeil to assess the statistical differences in the area under the ROC curve derived from the same cases. 13 As a sensitivity analysis to assess whether the timing of BBB disruption affected prognosis, we performed a restricted analysis on those patients for whom CSF and plasma protein data were available within 72 hours of injury. All statistical analyses were 2-tailed and were performed by using SPSS software version 20 (SPSS Inc., IBM). A p value < 0.05 was regarded as significant.
Results
Of the 252 patients who required decompressive craniectomy after severe TBI during 2004-2012, a total of 97 (39%) required an EVD to control intracranial pressure and 43 (44%) had biochemical evidence of BBB disruption (median total CSF protein concentration and CSF-plasma protein quotient 0.72 g × L -1 and 0.014 vs 0.13 g × L -1 and 0.004, respectively; p = 0.001 for both). Many patients who underwent decompressive craniectomy did not undergo EVD placement, either because their ventricles were considered too small for an EVD or because ICP was adequately controlled after surgical decompression and hence an EVD was not indicated. Biochemical evidence of BBB disruption was associated with more severe TBI (median predicted risk for unfavorable outcome 75% vs 63%, respectively; p = 0.001) and with worse outcomes at 6, 12, and 18 months (72% vs 37% unfavorable outcome at 18 months, respectively; p = 0.015) than was no BBB disruption ( Table 1) . As a continuous variable to reflect the severity of BBB disruption, the ratios of the total CSF protein concentration to total protein concentration also provided a reasonable ability to differentiate between favorable and favorable outcomes at 18 months after surgery (area under the ROC curve = 0.72, 95% CI 0.61-0.82) (Fig. 1) . The risk factor significantly associated with increased risk for BBB disruption was presence of nonevacuated intracerebral hematoma (> 1 cm diameter) (OR 3.03, 95% CI 1.23-7.50; p = 0.016) ( Table 2) .
Disruption of the BBB was associated with more se-vere TBI and worse long-term outcomes, and the ratios of the CSF protein to plasma protein concentration also provided a reasonable ability to differentiate between favorable and unfavorable long-term outcomes. Yet despite these findings, data on BBB disruption, when combined with the prognostic information contained in the CRASH model, did not seem to add significant prognostic value for differentiating between unfavorable and favorable outcomes at 6, 12, or 18 months after TBI (area under the ROC curve 0.855 vs 0.864, respectively; p = 0.453) ( Table 3) .
Sensitivity Analyses
On average, patients with biochemical evidence of BBB disruption required an EVD about 2 days later than those who did not have BBB disruption (4 days vs 2 days, respectively; p = 0.005). Restricting the analysis to pa- 
Discussion
The BBB is a dynamic interface that separates the brain from the circulatory system and plays a major role in maintaining a regulated microenvironment. Under normal circumstances, the BBB acts as a physical barrier and prevents diffusion of most water-soluble molecules larger than 500 D. After trauma, disruption of this barrier enables proteins to cross into the CNS, and measurement of protein levels within the CSF can be used to quantify the level of this disruption. 5, 10 The traditional method for assessing the functional status of the BBB is the CSF-plasma albumin quotient; however, we used the total CSF protein to total plasma protein ratio because we have found it to correlate well with the plasma albumin quotient (correlation coefficient 0.97).
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The results of this study confirm that among this group of patients, biochemical evidence of BBB disruption was associated with a more severe primary brain injury (as adjudged by the CRASH prognostic model) and worse long-term outcomes. The only single factor significantly associated with increased risk for BBB disruption was the presence of a nonevacuated hematoma, which probably reflects the value of this radiological finding when considering injury severity. This finding is notable because BBB disruption seems to be much less common among patients who have spontaneous intracerebral or subarachnoid hemorrhage than among patients with intracerebral hematoma after severe TBI. 19 What we were unable to demonstrate was that disruption of the BBB provided additional prognostic value over and above that which is contained in the CRASH prognostic model; therefore, it cannot be used as a marker of developing secondary brain injury. Disruption of the BBB might occur predominantly as a result of the primary injury, which has significant implications for clinical management. A recent post hoc analysis of a multicenter study that compared use of albumin versus saline as a resuscitation fluid showed that use of intravenous albumin was associated with higher ICP within the first week of TBI and worse long-term outcomes. 7 The results of our study support a hypothesis that intravenous albumin can be especially harmful when used in patients who have sustained a particularly severe TBI and who are therefore more likely to have significant BBB disruption. Albumin is a relatively large molecule (molecular weight 69 kD), and if albumin can leak through a BBB disruption after severe TBI, other smaller, osmotically active molecules, such as gelatin, could potentially also leak across the BBB and possibly worsen cerebral edema in patients after severe TBI. If so, consideration may have to be given to avoiding use of all intravenous colloid fluids in patients with biochemical evidence of BBB disruption or even in those patients with a large nonevacuated intracerebral hematoma.
The results of this study also have implications with regard to surrogate markers of prognosis. It has been confirmed that for patients who require a decompressive craniectomy, the CRASH prognostic model has an excellent ability to differentiate between unfavorable and favorable outcomes at 18 months. As such, the prognostic value of Fig. 1 . Area under the ROC curve of the ratios of total CSF protein concentration to total plasma protein concentration for differentiating between favorable and unfavorable outcomes at 18 months after decompressive craniectomy. any new biomarkers of severe TBI should be compared against the CRASH predicted risks for unfavorable outcome, 5 and the clinical utility of new biomarkers can be substantiated only if they can offer additional prognostic information over and above that provided by the CRASH prognostic model.
Notwithstanding these results, this study does have some limitations. It is well known that disruption of the BBB occurs over a variable time frame, 35 and we did not use a specific time at which either the ventricular catheter was inserted or at which sampling took place. In addition, although this series of patients with severe TBI and biochemical data on BBB disruption is one of the largest, the sample size is still small and the results are imprecise. As such, we cannot exclude a Type II error in concluding that a large nonevacuated intracerebral hematoma was the only significant risk factor for BBB disruption. Last, because we included only patients who had undergone a decompressive craniectomy and EVD placement, the incidence and prognostic value of BBB disruption in patients with a less severe form of TBI remains uncertain.
Conclusions
Biochemical evidence of BBB disruption was common among patients who had severe nonpenetrating TBI requiring decompressive craniectomy and an EVD, especially in the presence of a large nonevacuated intracerebral hematoma. Disruption of the BBB was more common among patients with a severe form of TBI and was associated with worse long-term outcomes; however, it did not seem to add significant prognostic value when combined with the prognostic information contained in the CRASH prognostic model. A multicenter study evaluating the incidence and prognostic significance of BBB disruption and its interactions with different types of intravenous fluid in patients with severe TBI is warranted.
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